Alexander Lazarev - Pressure Biosciences Chief Officer
| PBIODelisted Stock | USD 0.49 0.00 0.00% |
Executive
Dr. Alexander Lazarev, Ph.D., is the Vice President Research Development of Pressure BioSciences, Inc., since March 20, 2007. Prior to that, he served as Director of Research and Development, since joining the company in 2006. Prior to joining the company, Dr. Lazarev worked as a Visiting Scientist at the Barnett Institute of Chemical and Biological Analysis at Northeastern University in 2005, and served as a Director of New Technology Development at Proteome Systems, Inc., where he was involved in research and development of innovative proteomic analysis applications from 2001 until early 2006. From 1998 to 2001, Dr. Lazarev was employed as Senior Scientist at the Proteomics Division of Genomic Solutions, Inc. Prior to his employment at Genomic Solutions, Inc., Dr. Lazarev was employed in an analytical contract service startup company, PhytoChem Technologies, Inc., which was founded as a spinoff from ESA, Inc. in 1997. Previously, Dr. Lazarev held various scientific positions at the Ohio State University School of Medicine and the Uniformed Services University of Health Sciences. Most of his scientific career was dedicated to development of methods and applications for biochemical analysis. Since 2005, Dr. Lazarev was elected as an Executive Board member of the MASSEP.org, a nonprofit scientific discussion forum dedicated to the promotion and improvement of chromatography and other analytical technologies. Dr. Lazarev earned his undergraduate and graduate degrees at the University of Kazan, Russian Federation. since 2007.
| Age | 58 |
| Tenure | 17 years |
| Phone | 508 230 1828 |
| Web | https://www.pressurebiosciences.com |
Pressure Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9258) % which means that it has lost $0.9258 on every $100 spent on assets. This is way below average. Pressure Biosciences' management efficiency ratios could be used to measure how well Pressure Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Pressure Biosciences currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 2.04, implying the company greatly relies on financing operations through barrowing. Pressure Biosciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pressure Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Pressure Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pressure Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pressure to invest in growth at high rates of return. When we think about Pressure Biosciences' use of debt, we should always consider it together with cash and equity.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp. Pressure Biosciences operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 12 people. Pressure Biosciences [PBIO] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Pressure Biosciences is listed under Measuring and Control Equipment category by Fama And French industry classification. Management Performance
| Return On Asset | -0.93 |
Pressure Biosciences Leadership Team
Elected by the shareholders, the Pressure Biosciences' board of directors comprises two types of representatives: Pressure Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pressure. The board's role is to monitor Pressure Biosciences' management team and ensure that shareholders' interests are well served. Pressure Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pressure Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Schumacher, Founder, CEO and President Acting CFO, Treasurer, Secretary, Clerk and Director | ||
| ScD Ting, VP Engineering | ||
| Alexander Lazarev, Chief Officer | ||
| John Hollister, Director Marketing |
Pressure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Pressure Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.93 | ||||
| Operating Margin | (3.18) % | ||||
| Current Valuation | 33.23 M | ||||
| Shares Outstanding | 11.07 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 0.05 % | ||||
| Number Of Shares Shorted | 6.34 K | ||||
| Price To Earning | (1.05) X | ||||
| Price To Sales | 9.95 X | ||||
| Revenue | 2 M |
Pair Trading with Pressure Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pressure Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pressure Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Pressure OTC Stock
Moving against Pressure OTC Stock
| 0.88 | ELMD | Electromed | PairCorr |
| 0.87 | MYO | Myomo Inc | PairCorr |
| 0.86 | BSX | Boston Scientific Corp | PairCorr |
| 0.85 | PEN | Penumbra | PairCorr |
| 0.84 | OM | Outset Medical | PairCorr |
The ability to find closely correlated positions to Pressure Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pressure Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pressure Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pressure Biosciences to buy it.
The correlation of Pressure Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pressure Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pressure Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pressure Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Pressure OTC Stock
If you are still planning to invest in Pressure Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pressure Biosciences' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |